Cancer News and Research

Latest Cancer News and Research

Researchers identify molecular switch that controls inflammatory processes in aging-related disorders

A study led by Massachusetts General Hospital (MGH) investigators has identified what appears to be a molecular switch controlling inflammatory processes involved in conditions ranging from muscle atrophy to Alzheimer's disease.

14 Nov 2014

Study: Hedgehog cell signaling pathway may play role in breast cancer metastasis

Molecules called long non-coding RNAs (lncRNAs) have been implicated in breast cancer but exactly why they cause metastasis and tumor growth has been little understood…until now.

14 Nov 2014

Study gives a roadmap for future brain cancer vaccines

Glioblastoma is the most common aggressive primary brain tumor, and despite advances in standard treatment, the median survival is about 15 months (compared to 4 months without treatment).

14 Nov 2014

Oxytocin hormone inhibits fear center in brain, shows study

Frightening experiences do not quickly fade from memory. A team of researchers under the guidance of the University of Bonn Hospital has now been able to demonstrate in a study that the bonding hormone oxytocin inhibits the fear center in the brain and allows fear stimuli to subside more easily.

14 Nov 2014

New findings may help develo injury-prevention measures

This week's issue of the New England Journal of Medicine features an article that highlights an unprecedented analysis of the nation's childhood head injuries. The study, authored by

14 Nov 2014

Genetic testing, risk factor assessment could improve prevention strategies for breast cancer

Scientists used mathematical models to show that analysing genetic data, alongside a range of other risk factors, could substantially improve the ability to flag up women at highest risk of developing breast cancer.

14 Nov 2014

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides.

14 Nov 2014

Genticel completes patient enrollment for ProCervix phase II study

Genticel, a French biotechnology company and leading developer of therapeutic vaccines, today announces the completion of patient enrollment of the phase II study of its lead therapeutic vaccine candidate, ProCervix.

14 Nov 2014

Cornerstone's CPI-613 drug candidate chosen as 2014 Top 10 Most Interesting Oncology Projects to Watch

Cornerstone Pharmaceuticals, Inc., a development stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced that its lead compound CPI-613 has been chosen by Informa and Kantar Health as one of the 2014 Top 10 Most Interesting Oncology Projects to Watch.

14 Nov 2014

World-first transitional pain program aims to stop chronic pain following surgery

A world-first transitional pain program that aims to stop pain from becoming chronic after surgery is being pioneered at Toronto General Hospital, University Health Network.

14 Nov 2014

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

In six out of 10 cases, ovarian cancer is diagnosed when the disease is advanced and five-year survival is only 27 percent.

14 Nov 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

Representatives from 40 countries meet to discuss plan for antimicrobial resistance

Every year, 25,000 people die as a result of antimicrobial resistance in Europe. A global action plan against one of the greatest health threats of our time is the aim of a conference being held in Oslo on 13th-14th November.

14 Nov 2014

Sutter Health network hospitals recognized as ‘Top Performers on Key Quality Measures’

For the fourth year, The Joint Commission, the nation's leading accreditor of health care organizations, recognized hospitals in the Sutter Health network as among the nation's Top Performers on Key Quality Measures®. Sutter Health-affiliated hospitals have earned these quality recognitions each year since the program began in 2011.

13 Nov 2014

Cancer News and Research

Latest Cancer News and Research

Researchers identify molecular switch that controls inflammatory processes in aging-related disorders

Study: Hedgehog cell signaling pathway may play role in breast cancer metastasis

Study gives a roadmap for future brain cancer vaccines

Oxytocin hormone inhibits fear center in brain, shows study

New findings may help develo injury-prevention measures

Genetic testing, risk factor assessment could improve prevention strategies for breast cancer

Isis Pharmaceuticals, AstraZeneca partner to develop new delivery methods for antisense oligonucleotides

Genticel completes patient enrollment for ProCervix phase II study

Cornerstone's CPI-613 drug candidate chosen as 2014 Top 10 Most Interesting Oncology Projects to Watch

World-first transitional pain program aims to stop chronic pain following surgery

Chemotherapy drug combined with cancer-killing virus may treat recurrent ovarian cancer

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Representatives from 40 countries meet to discuss plan for antimicrobial resistance

Sutter Health network hospitals recognized as ‘Top Performers on Key Quality Measures’

Internet lessons, tailored text alerts can help young people adopt healthier lifestyles

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

University of Leeds researchers make new synthetic anti-cancer molecule

Researchers find key mechanism that could lead to new effective treatments for leukemias

U of G research may lead to novel treatment approaches for late-stage ovarian cancer

Bevacizumab–erlotinib combined efficacy may depend on VEGF level

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Newsletters you may be interested in